Inventiva SACA

Description of the Share Repurchase Program Authorised by the Ordinary General Meeting of 20 June 2024  

21 6 2024 16:05:00 提供 Nasdaq GlobeNewswire

Results of the votes of the Combined Shareholders’ General Meeting of June 20, 2024  

21 6 2024 16:00:00 提供 Nasdaq GlobeNewswire

Statement of total voting rights and shares forming the company’s share capital as of May 13, 2024

30 5 2024 02:30:00 提供 Nasdaq GlobeNewswire

Combined General Meeting of June 20, 2024 - Availability of the preparatory documents

30 5 2024 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva announces two scientific presentations at the EASL International Liver Congress™ 2024

22 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports 2024 First Quarter Financial Information¹ and provides a corporate update

21 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH

16 5 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the publication in Nature Communications of additional results from NATIVE Phase IIb clinical trial demonstrating improvement of markers of cardiometabolic health in patients with MASH/NASH treated with lanifibranor

13 5 2024 02:30:00 提供 Nasdaq GlobeNewswire

Inventiva announces filing of its 2023 Universal Registration Document and 2023 Annual Report on Form 20-F

03 4 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the nomination of Andre Turenne as Director

28 3 2024 03:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports its 2023 full-year results

27 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the schedule of publication and presentation of its 2023 Full-Year Financial Results

22 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces positive results from the Phase II, LEGEND, Proof-of-Concept study combining lanifibranor with empagliflozin in patients with MASH/NASH and T2D

18 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva to present the results of LEGEND Phase IIa combination trial with lanifibranor and empagliflozin in patients with MASH/NASH and T2D

13 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces that screening in the NATiV3, Phase III, clinical trial evaluating lanifibranor in NASH has resumed

07 3 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva reports preliminary 2023 fiscal year financial Information¹ and provides an update on its clinical trial NATiV3

15 2 2024 16:35:00 提供 Nasdaq GlobeNewswire

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

24 1 2024 16:15:00 提供 Nasdaq GlobeNewswire

Inventiva draws down the second tranche of €25 million under existing Finance Contract with the European Investment Bank

10 1 2024 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the randomization of the first patient in China in the NATiV3 clinical trial and provides an update on its clinical development program

20 12 2023 16:00:00 提供 Nasdaq GlobeNewswire

Inventiva announces the positive recommendation of the third DMC of the Phase III clinical trial with lanifibranor in patients with NASH

04 12 2023 16:05:00 提供 Nasdaq GlobeNewswire